AKTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Akari Therapeutics PLC (AKTX) is not a strong buy at this time for a beginner investor with a long-term strategy. While there are some positive developments, such as the appointment of a new Scientific Advisor and a Buy rating from Ladenburg with a $1 price target, the company's financials show no revenue and significant net losses. Additionally, there are no strong technical or proprietary trading signals indicating an immediate entry point. Given the lack of clear growth trends and the speculative nature of the stock, it is better to hold off on investing in AKTX for now.
The MACD is positive and expanding, indicating mild bullish momentum. The RSI is neutral at 69.531, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot point of 0.25, with resistance at 0.267 and 0.277, and support at 0.233 and 0.223.
Ladenburg initiated coverage with a Buy rating and a $1 price target.
The company has no revenue, significant net losses (-$6.4 million in Q3 2025), and no recent trading trends from hedge funds or insiders. The stock is speculative and lacks clear growth trends.
In Q3 2025, the company reported no revenue, a net loss of $6.4 million (up 121.07% YoY), and no EPS or gross margin improvements.
Ladenburg initiated coverage on January 5, 2026, with a Buy rating and a $1 price target.
